镭-223使用中的眼部并发症:病例系列
本文报告三例转移性前列腺腺癌患者使用镭-223后出现眼部并发症,表现为视物模糊,正式诊断包括葡萄膜炎和前房积血。作者认为这些眼部并发症可能与辐射对新血管形成的潜在影响、多重用药或镭-223对整合信号蛋白的分子生物学效应有关,也可能与 underlying 眼部健康状况不佳有关。
要点
- 镭-223治疗转移性去势抵抗性前列腺癌后可能出现眼部并发症。
- 眼部并发症表现为视物模糊,诊断包括葡萄膜炎和前房积血。
- 作者提出眼部并发症可能与辐射对新血管形成的影响、多重用药或镭-223的分子效应有关。
核心结论
- 作者认为这些眼部并发症可能是辐射对新血管形成的潜在影响、多重用药或镭-223对整合信号蛋白的分子生物学效应所致,并可能与 underlying 眼部健康状况不佳有关。
- 不良事件的记录非常重要,因为转移性前列腺癌发病率高且镭-223在其他成骨性疾病中的应用兴趣日益增加。
研究设计与样本
- 病例系列,报告三例转移性前列腺腺癌患者使用镭-223后出现的眼部并发症。
主要发现
- 三例患者使用镭-223后出现眼部并发症,表现为视物模糊。
- 正式诊断包括葡萄膜炎和前房积血。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radium-223 is used for the treatment of osseous metastases in castrate-resistant prostate cancer, and has been shown to increase time to the first skeletal-related event, reduce the rate of hospitalization, and improve quality of life. It is well tolerated, with hematologic toxicity as the main adverse event. Thus far, no ocular complication has been reported in the literature after initial administration of radium-223 with a single case reported of ocular complications after a patient's second course of radium-223. CASE PRESENTATIONS: We present three cases of ocular complications after the use of radium-223 in patients with metastatic prostatic adenocarcinoma. Ocular complications presented as blurry vision, and formal diagnosis included uveitis and hyphema. CONCLUSIONS: Documentation of adverse events is exceedingly important due to the high incidence of metastatic prostate cancer and increasing interest for the use of radium-223 in other osteoblastic disease. The authors postulate that these ocular complications may be a result of radiation's potential effect on neovascularization, polypharmacy, or the biomolecular effects of radium-223 on integral signaling proteins, potentially coupled with poor underlying ocular health.
引用
- Bloom JR, Castillejos AG, Jones B, et al. Ocular complications with the use of radium-223: a case series. Radiat Oncol. 2022. PMID: 35581667. doi:10.1186/s13014-022-02060-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。